Verona Pharma (NASDAQ:VRNA – Get Free Report) is scheduled to release its earnings data before the market opens on Monday, November 4th. Analysts expect Verona Pharma to post earnings of ($0.44) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.
Verona Pharma (NASDAQ:VRNA – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.53). During the same period in the prior year, the company posted ($0.11) EPS. On average, analysts expect Verona Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Verona Pharma Trading Down 1.7 %
NASDAQ:VRNA opened at $33.86 on Monday. The firm has a market capitalization of $2.75 billion, a P/E ratio of -21.99 and a beta of 0.44. The company has a debt-to-equity ratio of 0.72, a current ratio of 8.61 and a quick ratio of 8.61. Verona Pharma has a one year low of $11.39 and a one year high of $35.62. The company’s 50-day simple moving average is $29.96 and its 200 day simple moving average is $21.54.
Insider Activity
Analyst Ratings Changes
A number of brokerages recently weighed in on VRNA. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of Verona Pharma in a report on Tuesday, October 1st. Wells Fargo & Company began coverage on Verona Pharma in a research report on Thursday, October 3rd. They set an “overweight” rating and a $50.00 price objective on the stock. Canaccord Genuity Group boosted their target price on Verona Pharma from $35.00 to $37.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Finally, Truist Financial raised their price target on shares of Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $39.33.
View Our Latest Research Report on VRNA
Verona Pharma Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Recommended Stories
- Five stocks we like better than Verona Pharma
- Low PE Growth Stocks: Unlocking Investment Opportunities
- GM’s Lithium Americas Deal Positions It for EV Dominance
- What is a Death Cross in Stocks?
- Amazon: Why Analysts Think It’s A Solid Buy Ahead Of Earnings
- What is the S&P 500 and How It is Distinct from Other Indexes
- NextEra’s Diverse Business Is Set to Win As Energy Demand Rises
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.